Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

The Senate is expected to clear a procedural hurdle Wednesday to approve Robert F. Kennedy Jr. as Health and Human Services ...

Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment.

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...